News from Friday, April 10, 2026
Articles
CMS' MFN Proposals Won't Help Seniors Despite Lofty Promises
(4/9, Brianna Allen, PhRMA Blog) comments "...These MFN proposals may reshuffle payments in Washington, but they don’t fix what seniors actually pay at the pharmacy or the doctor’s office. To meaningfully lower costs for Americans, policymakers need to address the real drivers of high health care spending—insurers and middlemen, abuses in the 340B hospital markup program, and the fact that foreign governments underpay for medicines. Focusing on these issues is how the country can deliver real, lasting reductions in patients’ out-of-pocket costs." Full
UK: MHRA and NICE Roll out New Joint Pathways to Accelerate Access to New Medicines
(4/10, The Evidence Base) reports “...Professor Jonathan Benger, Chief Executive of NICE, noted that ‘by working more closely with our partners at the MHRA, we can get medicines into the NHS faster, helping to improve peoples’ health, ease pressure on NHS services and support a strong life sciences industry in this country.’ Lawrence Tallon, Chief Executive of the MHRA, added that ‘our continued collaboration also makes the UK an even more attractive launch market for the global life sciences industry so will boost R&D investment and economic growth in this country.’” Full
Press Releases
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
(4/9, Tempus Press Release) “...‘By providing access to the Tempus multimodal data library, we are empowering the Gilead team to further fuel its R&D engine with AI-driven insights,’ said Ryan Fukushima, CEO of Tempus Data & Apps. ‘We are thrilled to expand this collaboration, offering the multimodal depth necessary to uncover critical biological insights. This approach helps navigate billions of data points to find the “signal in the noise,” ultimately increasing the probability of success for life-altering medicines.’” Full
Precision Medicine Tools Offer Hope for Patients with Rare Blood Cancers
(4/9, Weill Cornell Medicine Press Release) “...Peripheral T-cell lymphomas comprise diverse blood cancers that have a distinct biology, and survival rates vary widely. Lymphoma specialist Dr. Jia Ruan, a professor of clinical medicine at Weill Cornell Medicine, and her collaborators are working to change that. ‘We previously thought that we could treat all non-Hodgkin lymphomas with a one-size-fits-all model. We are learning we really have to develop personalized diagnostic, treatment and prognostic models for T-cell lymphomas.’” Full
Journals
Comparative Effectiveness of Dexamethasone Versus Methylprednisolone for Neuropathic Outcomes after Combined Spinal-Epidural Labor Analgesia: A Prospective, Randomized, Double-Blind Trial
Bo Liu, et al.
March 25, 2026, Frontiers in Medicine
Ketamine Versus Alternate Agents to Prevent Postinduction Haemodynamic Instability During Tracheal Intubation of Critically Ill Adults: A Systematic Review and Meta-Analysis
Daniel Loughnan, et al.
April 7, 2026, British Journal of Anaesthesia
British Journal of Anaesthesia
Comparative Outcomes of Intra-Articular, Subchondral, and Combined Injections of Peripheral Blood Mesenchymal Stromal Cells in Knee Osteoarthritis
Harish V K Ratna, et al.
April 18, 2026, World Journal of Orthopedics
Matching-Adjusted Indirect Comparison Analysis of Omalizumab Versus Dupilumab in Patients with Chronic Spontaneous Urticaria
Giselle Mosnaim, MD, et al.
May 2026, The Journal of Allergy and Clinical Immunology